HK Stock Market Move | CSTONE PHARMA-B (02616) rose more than 9% in the morning session. GIC increased its holdings in the company again after nearly two months, with its stake now reaching 6%.

CSTONE PHARMA-B (02616) rose more than 9% in early trading, rising 6.11% to HK$7.29 as of press time, with a turnover of HK$120.48 million. On the news front, according to the latest information from the Hong Kong Stock Exchange, GIC disclosed on October 13 that it once again increased its stake in CSTONE PHARMA-B, reaching a 6% holding. This is GIC's second major increase in less than two months on August 18, GIC had previously significantly increased its stake in CSTONE PHARMA-B by 80.4 million shares, costing over HK$630 million. It is worth noting that CSTONE PHARMA-B announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Gexibustat as a monotherapy for the treatment of advanced unresectable stage III non-small cell lung cancer (NSCLC) in adult patients with PD-L1 expression 1%, without epidermal growth factor receptor (EGFR) sensitive mutations or ALK, ROS1 gene rearrangements, and no disease progression after platinum-based chemotherapy (CRT).